Key result
RAS blockade provides much smaller BP-independent renoprotection in chronic kidney disease than what is due to its antihypertensive effects, suggesting its specific benefits are overemphasized.
Why the study?
Does renin-angiotensin system (RAS) blockade provide significant blood pressure-independent renoprotection in patients with chronic kidney disease?
Does renin-angiotensin system (RAS) blockade provide significant blood pressure-independent renoprotection in patients with chronic kidney disease?
This review suggests that the specific, blood pressure-independent renoprotective benefits of RAS blockade in chronic kidney disease have been greatly overemphasized compared to its primary antihypertensive effects.
No takes yet. Share an insight, caveat, or question.
Emphasize BP control with RAS blockade in CKD; leaves open the true magnitude of any BP-independent renoprotection.
Griffin et al. (2006) conducted a review in Chronic kidney disease. Renin-angiotensin system (RAS) blockade was evaluated on BP-independent renoprotection. RAS blockade provides much smaller BP-independent renoprotection in chronic kidney disease than what is due to its antihypertensive effects, suggesting its specific benefits are overemphasized.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: